Clinical Trial Update: Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of Hsp90 inhibitor STA-9090 (ganetespib) in relapsed or refractory small cell lung cancer has completed; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• STA-9090 (ganetespib)

Snippet

Sponsor: David M. Jackman, MD | Conditions: Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-04-11